Total Tregs, of which Helios+ Tregs accounted for the majority, were enriched in patients with early-stage cancer and improved outcomes, consistent with the preponderance of prior studies of Tregs in CRC (21, 22). The gene discussed is IKZF2; the disease is colorectal carcinoma.